NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$135.16 +0.07 (+0.05 %)
(As of 07/22/2018 04:00 PM ET)
Previous Close$135.16
Today's Range$134.0101 - $135.78
52-Week Range$102.10 - $149.34
Volume1.30 million shs
Average Volume1.22 million shs
Market Capitalization$30.07 billion
P/E Ratio26.19
Dividend YieldN/A
Beta1.08
Alexion Pharmaceuticals logoAlexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops cPMP (cyclic Pyranopterin Monophosphate) (ALXN 1101) for molybdenum cofactor deficiency disease type A; and Samalizumab (ALXN6000), an immunomodulatory humanized monoclonal antibody. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

Receive ALXN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALXN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ALXN
CUSIP01535110
Phone475-230-2596

Debt

Debt-to-Equity Ratio0.33
Current Ratio3.35
Quick Ratio2.86

Price-To-Earnings

Trailing P/E Ratio26.19
Forward P/E Ratio21.49
P/E Growth1.22

Sales & Book Value

Annual Sales$3.55 billion
Price / Sales8.47
Cash Flow$8.0357 per share
Price / Cash16.82
Book Value$39.81 per share
Price / Book3.40

Profitability

EPS (Most Recent Fiscal Year)$5.16
Net Income$443.30 million
Net Margins14.46%
Return on Equity13.70%
Return on Assets9.00%

Miscellaneous

Employees2,525
Outstanding Shares222,500,000
Market Cap$30,073.24

Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

How will Alexion Pharmaceuticals' stock buyback program work?

Alexion Pharmaceuticals announced that its board has approved a stock buyback plan on Sunday, April 9th 2017, which authorizes the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 3.4% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's board of directors believes its shares are undervalued.

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its quarterly earnings data on Thursday, April, 26th. The biopharmaceutical company reported $1.68 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.50 by $0.18. The biopharmaceutical company had revenue of $930.90 million for the quarter, compared to analysts' expectations of $920.50 million. Alexion Pharmaceuticals had a return on equity of 13.70% and a net margin of 14.46%. The company's revenue for the quarter was up 7.0% on a year-over-year basis. During the same period last year, the firm posted $1.38 earnings per share. View Alexion Pharmaceuticals' Earnings History.

When is Alexion Pharmaceuticals' next earnings date?

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Alexion Pharmaceuticals.

What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?

Alexion Pharmaceuticals issued an update on its FY18 earnings guidance on Thursday, April, 26th. The company provided earnings per share (EPS) guidance of $6.75-6.90 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.82. The company issued revenue guidance of $3.925-3.985 billion, compared to the consensus revenue estimate of $3.98 billion.

What price target have analysts set for ALXN?

18 analysts have issued 12-month price objectives for Alexion Pharmaceuticals' stock. Their forecasts range from $130.00 to $180.00. On average, they expect Alexion Pharmaceuticals' stock price to reach $161.1765 in the next twelve months. This suggests a possible upside of 19.2% from the stock's current price. View Analyst Ratings for Alexion Pharmaceuticals.

What is the consensus analysts' recommendation for Alexion Pharmaceuticals?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 18 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Alexion Pharmaceuticals' key competitors?

Who are Alexion Pharmaceuticals' key executives?

Alexion Pharmaceuticals' management team includes the folowing people:
  • Dr. Ludwig N. Hantson, CEO & Director (Age 55)
  • Mr. Paul J. Clancy, Exec. VP & CFO (Age 56)
  • Mr. Brian Goff, Exec. VP & Chief Commercial Officer (Age 49)
  • Daniel A. Bazarko CPA, Chief Accounting Officer and Sr. VP
  • Ms. Indrani M. Lall Franchini, Exec. VP & Chief Compliance Officer (Age 46)

Has Alexion Pharmaceuticals been receiving favorable news coverage?

News stories about ALXN stock have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alexion Pharmaceuticals earned a news sentiment score of 0.14 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 45.61 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Alexion Pharmaceuticals' major shareholders?

Alexion Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Swedbank (0.37%), Bank of Montreal Can (0.30%), Factory Mutual Insurance Co. (0.27%), Assenagon Asset Management S.A. (0.14%), Boston Advisors LLC (0.11%) and Peregrine Capital Management LLC (0.07%). Company insiders that own Alexion Pharmaceuticals stock include Alvin S Parven, Ann M Veneman, Bros Advisors Lp Baker, Carsten Thiel, Christopher J Coughlin, Clare Carmichael, David Hallal, Edward Miller, Heidi L Wagner, John B Moriarty, John J Orloff, Julie O'neill, Leonard Bell, Ludwig Hantson, Paul J Clancy and Vikas Sinha. View Institutional Ownership Trends for Alexion Pharmaceuticals.

Which major investors are selling Alexion Pharmaceuticals stock?

ALXN stock was sold by a variety of institutional investors in the last quarter, including Stralem & Co. Inc., Channing Capital Management LLC, Hartford Investment Management Co., Covenant Asset Management LLC, Creative Planning, Handelsbanken Fonder AB, Gateway Investment Advisers LLC and Sit Investment Associates Inc.. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Ann M Veneman, Heidi L Wagner, John B Moriarty, John J Orloff, Julie O'neill, Ludwig Hantson and Paul J Clancy. View Insider Buying and Selling for Alexion Pharmaceuticals.

Which major investors are buying Alexion Pharmaceuticals stock?

ALXN stock was bought by a variety of institutional investors in the last quarter, including Swedbank, Assenagon Asset Management S.A., Factory Mutual Insurance Co., Bank of Montreal Can, Vigilant Capital Management LLC, Boston Advisors LLC, Oakbrook Investments LLC and Mitsubishi UFJ Asset Management UK Ltd.. Company insiders that have bought Alexion Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Christopher J Coughlin and Ludwig Hantson. View Insider Buying and Selling for Alexion Pharmaceuticals.

How do I buy shares of Alexion Pharmaceuticals?

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alexion Pharmaceuticals' stock price today?

One share of ALXN stock can currently be purchased for approximately $135.16.

How big of a company is Alexion Pharmaceuticals?

Alexion Pharmaceuticals has a market capitalization of $30.07 billion and generates $3.55 billion in revenue each year. The biopharmaceutical company earns $443.30 million in net income (profit) each year or $5.16 on an earnings per share basis. Alexion Pharmaceuticals employs 2,525 workers across the globe.

How can I contact Alexion Pharmaceuticals?

Alexion Pharmaceuticals' mailing address is 100 COLLEGE STREET, NEW HAVEN CT, 06510. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]


MarketBeat Community Rating for Alexion Pharmaceuticals (NASDAQ ALXN)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  967 (Vote Outperform)
Underperform Votes:  510 (Vote Underperform)
Total Votes:  1,477
MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALXN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALXN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Featured Article: Earnings Per Share

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.